Assertio CEO Brendan O’Grady to depart, Mark Reisenauer to succeed

Assertio (ASRT) Holdings has appointed director Mark Reisenauer as the Company’s CEO. As part of this transition, current CEO Brendan O’Grady will be departing the Company. Reisenauer, who joined Assertio’s Board in January 2025, previously served as President of U.S. Commercial at Astellas Pharmaceuticals Heather Mason, Chair of the Board of Directors, stated, “After significant deliberation, the Board determined that Mark is best suited to lead Assertio through its next phase. As we enter 2026, our goal is to accelerate growth while enhancing efficiency to deliver long-term value for shareholders and patients. Given Mark’s extensive experience successfully building and launching franchises and products in both the oncology and specialty spaces and his in-depth knowledge of our business, he is highly qualified to take on this role. In Mark’s new role, Assertio stakeholders will be able to further benefit from his track record of leading commercially driven organizations, creating strategies, driving lifecycle management and assessing business development opportunities.”